Developer docs
API playgroundTry for free, no card

Search company profiles

Uneedle

Full company profile

uuid002jhcy

Namestring
Uneedle
Legal namestring
U-Needle B.V.
Websiteurl
uneedle.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Uneedle (legal entity: U-Needle B.V.) is a Dutch medical device company founded in 2008 and headquartered in Enschede, Netherlands, specializing in the design and manufacture of proprietary silicon microneedle drug delivery devices. The company leverages semiconductor MEMS manufacturing processes — specifically crystal plane etching — to produce atom-sharp hollow needle cannulas with ultra-short bevels that are difficult to replicate using conventional steel needle grinding techniques. Uneedle operates two product platforms: the Bella-mu intradermal delivery system (lead product Bella-mu 1.4mm, CE marked and FDA 510(k) cleared) for cancer vaccines, prophylactic vaccines, and aesthetic applications, and the Bella-Vue suprachoroidal ophthalmic system (lead product Bella-Vue 1.0mm) for retinal disease therapeutics. Both product lines are manufactured in-house at GMP-compliant cleanroom facilities on the University of Twente campus, supported by a full-scope ISO 13485 quality management system.

The company serves enterprise pharmaceutical and biotechnology customers through a B2B model combining hardware sales of CE/FDA-cleared needle products, licensing of proprietary technology, and custom product development services. Its go-to-market is consultative enterprise sales (sales@uneedle.com) targeting partners developing intradermal and suprachoroidal therapies, with disclosed engagements including BriaCell Therapeutics (Phase 3 metastatic breast cancer candidate Bria-IMT, NCT06072612), Aston Sci (Korean cancer vaccine trial NCT05163223), and UMC Leiden (vaccine dose-sparing research). Notable customers in the data include BriaCell Therapeutics, Aston Sci, and UMC Leiden, reflecting an enterprise pharmaceutical and academic customer profile.

Uneedle's business model centers on a small-dedicated-team structure (11-50 employees) generating revenue through a mix of regulated medical device product sales, technology licensing royalties, and bespoke design/development services. The company positions itself as a co-development partner rather than a pure component supplier, with the 2026 MoU with BriaCell establishing a commercial supply framework contingent on Phase 3 success. Distribution is direct B2B with no intermediary channels, and the regulatory footprint spans the EU and US markets via CE and FDA clearances, with global reach subject to regional approvals.

Short descriptiontext

Uneedle (U-Needle B.V.) is a Dutch medical device company that designs and manufactures proprietary silicon microneedle drug delivery devices for pharmaceutical partners, serving ophthalmic, cancer vaccine, and immunotherapy applications through its Bella-Vue and Bella-mu platforms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEnschede, Netherlands
HQ citystring
Enschede
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
silicon microneedles, intradermal drug delivery, suprachoroidal injection devices, medical device manufacturing, ophthalmic drug delivery
Industry1 code
PRIMARYHLAHADAM
Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Devices - Microneedle Drug Delivery
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Silicon Microneedle Product Sales
TypeHardware Sales
Description

Sale of proprietary silicon microneedles and microneedle-based drug delivery devices including Bella-Vue (suprachoroidal) and Bella-mu (intradermal) product families. Products are CE marked and FDA 510(k) cleared medical devices.

uneedle.com
2Licensing
TypeLicensing Royalties
Description

Licensing of proprietary technology and existing products to pharmaceutical companies for use in their therapies. Companies can license Uneedle's designs for custom development built on proprietary microneedle technology.

uneedle.com
3Custom Product Development
TypeProfessional Services
Description

Design and development services to translate customer requirements into custom microneedle designs. Full scope Quality Management System yielding needle designs that fulfill customer and regulatory requirements.

uneedle.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Infrastructure, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Bella-Vue
Description

Ophthalmic microneedle platform designed for suprachoroidal injections to facilitate precise delivery of small molecules or biologics to the back of the eye. Clinical lead product is Bella-Vue 1.0 with an effective needle length of 1.0 mm.

uneedle.com
+1 more record
Core offering1 text field

Uneedle designs, develops, and manufactures proprietary silicon microneedle-based drug delivery devices for pharmaceutical partners, organized into two product platforms: Bella-Vue for suprachoroidal ophthalmic injections (targeting retinal diseases such as wet/dry AMD, diabetic retinopathy, and macular edema) and Bella-mu for intradermal injections (used in cancer vaccines, viral infection vaccines, and aesthetic treatments). Lead commercial products include the Bella-Vue 1.0 and Bella-mu 1.4 mm needles, both manufactured in-house at GMP-compliant cleanroom facilities in the Netherlands. The company also provides custom product development services and licenses its proprietary microneedle technology to pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Uneedle offers a proprietary silicon microneedle technology platform for drug delivery, organized into two product families: the Bella-Vue platform for suprachoroidal ophthalmic injections targeting retinal diseases, and the Bella-mu platform for intradermal injections used in cancer vaccines, viral infections, and aesthetics. The company provides both off-the-shelf needle products (Bella-Vue 1.0, Bella-mu 1.4 mm) and custom development/manufacturing services. All products are manufactured in-house at GMP-compliant facilities in the Netherlands using semiconductor processes, and are CE certified and FDA 510(k) cleared.

Product and service6 records
1Bella-Vue Platform
2Bella-Vue 1.0
3Bella-mu Platform
4Bella-mu 1.4 mm
5GMP Compliant Manufacturing Services
6Product Development Services
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-25
Description

BriaCell Therapeutics has entered into a Memorandum of Understanding with Uneedle to support commercial readiness of Bria-IMT (Phase 3 clinical candidate for metastatic breast cancer) using Uneedle's proprietary intradermal microneedle technology. The technology is currently being used in BriaCell's pivotal Phase 3 study (ClinicalTrials.gov identifier: NCT06072612). The non-binding MoU establishes a plan for scaling Uneedle's microneedle devices for commercial quantities, contingent upon successful regulatory approval of Bria-IMT.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-25
Description

Partnership with BriaCell for intradermal administration of lead Phase 3 clinical candidate Bria-IMT for metastatic breast cancer treatment. Supporting commercial readiness of Uneedle's proprietary microneedle technology.

3Aston Sci
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Korean company using Bella-mu silicon microneedles in a clinical trial (NCT05163223) to deliver cancer vaccination therapy targeting breast cancer. Demonstrates application in therapeutic cancer vaccination.

uneedle.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with UMC Leiden demonstrated 5x dose-sparing potential of Bella-mu compared to standard intramuscular injection for Spikevax (Moderna), validating dose-sparing capabilities for viral infection vaccines.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Vaxxas develops high-density microneedle patches (Nanopatch) for vaccine and therapeutic intradermal delivery. Direct peer: both companies target the same pharmaceutical-decision-maker with microneedle-based intradermal drug delivery, overlapping in cancer vaccine, viral vaccine, and dose-sparing use cases.

TypeBroad incumbent
Description

3M Drug Delivery Systems is a leading manufacturer of transdermal patches and microneedle technologies (via the 3M Microstructured Transdermal System) used by pharmaceutical partners. Broad incumbent: large device manufacturer with adjacent microneedle drug delivery offering, with greater resources and broader commercial reach than Uneedle.

TypeBroad incumbent
Description

Kindeva Drug Delivery (formerly 3M Drug Delivery) is a contract drug delivery manufacturer offering transdermal, microneedle, and inhalation delivery solutions to pharma partners. Broad incumbent: serves the same pharmaceutical co-development customer set with comparable microneedle and transdermal capabilities at much larger scale.

TypeDirect peer
Description

PharmaJet provides needle-free jet injection systems (Stratis and Tropis) for intradermal and intramuscular vaccine administration. Direct peer in vaccine delivery: targets the same pharmaceutical partners for dose-sparing intradermal administration, with an alternative (jet) mechanism.

TypeBroad incumbent
Description

Corium, now part of LTS Lurb, develops transdermal drug delivery systems including microneedle-based platforms. Broad incumbent: established transdermal delivery company with overlapping customer base in pharmaceutical drug delivery, but operating at much greater scale and with broader product portfolio.

TypeDirect peer
Description

Micron Biomedical develops dissolvable microneedle patches for vaccines (measles, flu, polio) and is backed by program grants including from the Gates Foundation. Direct peer: same end customer (vaccine developers), same delivery route (intradermal), competing mechanism of action.

TypeDirect peer
Description

Nanopass is an Israeli microneedle company with silicon-based micron-scale needle technologies used for intradermal delivery in vaccines and therapeutics. Closest technology peer: both use semiconductor-process silicon microneedles and target identical intradermal pharmaceutical application areas.

TypeBroad incumbent
Description

Becton Dickinson is a global medical device company making injection and drug delivery devices including prefillable syringes, auto-injectors, and intradermal needles. Broad incumbent: dominant incumbent in injection drug delivery with established pharma distribution; potentially positioned as an acquirer or competitor in the microneedle niche.

TypeDirect peer
Description

Clearside has the approved suprachoroidal injection platform SCS Microinjector used in Xipere for macular edema and is partnering with retinal therapy developers. Direct Bella-Vue competitor: same suprachoroidal drug delivery procedure, same ophthalmology pharmaceutical customer, same retinal disease indications.

TypeOthers
Description

West Pharmaceutical Services is a leading provider of primary packaging, delivery systems, and contract development services for injectable pharmaceutical products. Enabler/ecosystem peer: not a direct microneedle competitor, but the supplier-of-record and contract manufacturer of injection/packaging components used in combination products.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Uneedle

Medical Devices - Microneedle Drug Deliveryuneedle.com

Uneedle (U-Needle B.V.) is a Dutch medical device company that designs and manufactures proprietary silicon microneedle drug delivery devices for pharmaceutical partners, serving ophthalmic, cancer vaccine, and immunotherapy applications through its Bella-Vue and Bella-mu platforms.

What Uneedle does

Uneedle (legal entity: U-Needle B.V.) is a Dutch medical device company founded in 2008 and headquartered in Enschede, Netherlands, specializing in the design and manufacture of proprietary silicon microneedle drug delivery devices. The company leverages semiconductor MEMS manufacturing processes — specifically crystal plane etching — to produce atom-sharp hollow needle cannulas with ultra-short bevels that are difficult to replicate using conventional steel needle grinding techniques. Uneedle operates two product platforms: the Bella-mu intradermal delivery system (lead product Bella-mu 1.4mm, CE marked and FDA 510(k) cleared) for cancer vaccines, prophylactic vaccines, and aesthetic applications, and the Bella-Vue suprachoroidal ophthalmic system (lead product Bella-Vue 1.0mm) for retinal disease therapeutics. Both product lines are manufactured in-house at GMP-compliant cleanroom facilities on the University of Twente campus, supported by a full-scope ISO 13485 quality management system.

The company serves enterprise pharmaceutical and biotechnology customers through a B2B model combining hardware sales of CE/FDA-cleared needle products, licensing of proprietary technology, and custom product development services. Its go-to-market is consultative enterprise sales (sales@uneedle.com) targeting partners developing intradermal and suprachoroidal therapies, with disclosed engagements including BriaCell Therapeutics (Phase 3 metastatic breast cancer candidate Bria-IMT, NCT06072612), Aston Sci (Korean cancer vaccine trial NCT05163223), and UMC Leiden (vaccine dose-sparing research). Notable customers in the data include BriaCell Therapeutics, Aston Sci, and UMC Leiden, reflecting an enterprise pharmaceutical and academic customer profile.

Uneedle's business model centers on a small-dedicated-team structure (11-50 employees) generating revenue through a mix of regulated medical device product sales, technology licensing royalties, and bespoke design/development services. The company positions itself as a co-development partner rather than a pure component supplier, with the 2026 MoU with BriaCell establishing a commercial supply framework contingent on Phase 3 success. Distribution is direct B2B with no intermediary channels, and the regulatory footprint spans the EU and US markets via CE and FDA clearances, with global reach subject to regional approvals.

Uneedle firmographics

Firmographics
Name
Uneedle
Legal name
U-Needle B.V.
Website
https://uneedle.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Uneedle (U-Needle B.V.) is a Dutch medical device company that designs and manufactures proprietary silicon microneedle drug delivery devices for pharmaceutical partners, serving ophthalmic, cancer vaccine, and immunotherapy applications through its Bella-Vue and Bella-mu platforms.
Ownership category
akta.pro rank

Uneedle industry classification

Industry
Product category
Medical Devices - Microneedle Drug Delivery
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHADAM
Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment

Keywords

  • Silicon microneedles
  • Intradermal drug delivery
  • Suprachoroidal injection devices
  • Medical device manufacturing
  • Ophthalmic drug delivery

Where Uneedle is headquartered

Location

Headquarters

HQ city
Enschede
HQ country
Netherlands
HQ region
Europe

Offices2 records

Markets served

Uneedle business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Infrastructure, Personnel, Operations, Marketing or Sales

Revenue model

  1. Silicon Microneedle Product Sales: Sale of proprietary silicon microneedles and microneedle-based drug delivery devices including Bella-Vue (suprachoroidal) and Bella-mu (intradermal) product families. Products are CE marked and FDA 510(k) cleared medical devices.
  2. Licensing: Licensing of proprietary technology and existing products to pharmaceutical companies for use in their therapies. Companies can license Uneedle's designs for custom development built on proprietary microneedle technology.
  3. Custom Product Development: Design and development services to translate customer requirements into custom microneedle designs. Full scope Quality Management System yielding needle designs that fulfill customer and regulatory requirements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Uneedle product offering

Product offering

Core offering

Uneedle designs, develops, and manufactures proprietary silicon microneedle-based drug delivery devices for pharmaceutical partners, organized into two product platforms: Bella-Vue for suprachoroidal ophthalmic injections (targeting retinal diseases such as wet/dry AMD, diabetic retinopathy, and macular edema) and Bella-mu for intradermal injections (used in cancer vaccines, viral infection vaccines, and aesthetic treatments). Lead commercial products include the Bella-Vue 1.0 and Bella-mu 1.4 mm needles, both manufactured in-house at GMP-compliant cleanroom facilities in the Netherlands. The company also provides custom product development services and licenses its proprietary microneedle technology to pharmaceutical companies.

Product overview

Uneedle offers a proprietary silicon microneedle technology platform for drug delivery, organized into two product families: the Bella-Vue platform for suprachoroidal ophthalmic injections targeting retinal diseases, and the Bella-mu platform for intradermal injections used in cancer vaccines, viral infections, and aesthetics. The company provides both off-the-shelf needle products (Bella-Vue 1.0, Bella-mu 1.4 mm) and custom development/manufacturing services. All products are manufactured in-house at GMP-compliant facilities in the Netherlands using semiconductor processes, and are CE certified and FDA 510(k) cleared.

Differentiator

Problem solved

Functional benefit

Brands

  • Bella-Vue: Ophthalmic microneedle platform designed for suprachoroidal injections to facilitate precise delivery of small molecules or biologics to the back of the eye. Clinical lead product is Bella-Vue 1.0 with an effective needle length of 1.0 mm.
  • Bella-mu

Products and services

  • Bella-Vue Platform
  • Bella-Vue 1.0
  • Bella-mu Platform
  • Bella-mu 1.4 mm
  • GMP Compliant Manufacturing Services
  • Product Development Services

Companies that use Uneedle

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Uneedle technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Uneedle partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • BriaCell TherapeuticscoreStrategic or Co-development Partner · 25 June 2026BriaCell Therapeutics has entered into a Memorandum of Understanding with Uneedle to support commercial readiness of Bria-IMT (Phase 3 clinical candidate for metastatic breast cancer) using Uneedle's proprietary intradermal microneedle technology. The technology is currently being used in BriaCell's pivotal Phase 3 study (ClinicalTrials.gov identifier: NCT06072612). The non-binding MoU establishes a plan for scaling Uneedle's microneedle devices for commercial quantities, contingent upon successful regulatory approval of Bria-IMT.
  • BriaCell TherapeuticscoreStrategic or Co-development Partner · 25 June 2026Partnership with BriaCell for intradermal administration of lead Phase 3 clinical candidate Bria-IMT for metastatic breast cancer treatment. Supporting commercial readiness of Uneedle's proprietary microneedle technology.
  • Aston ScicoreStrategic or Co-development PartnerKorean company using Bella-mu silicon microneedles in a clinical trial (NCT05163223) to deliver cancer vaccination therapy targeting breast cancer. Demonstrates application in therapeutic cancer vaccination.
  • UMC LeidencoreStrategic or Co-development PartnerPartnership with UMC Leiden demonstrated 5x dose-sparing potential of Bella-mu compared to standard intramuscular injection for Spikevax (Moderna), validating dose-sparing capabilities for viral infection vaccines.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Uneedle competitors and assessment

Company assessment

Direct peers

  • Vaxxas: Vaxxas develops high-density microneedle patches (Nanopatch) for vaccine and therapeutic intradermal delivery. Direct peer: both companies target the same pharmaceutical-decision-maker with microneedle-based intradermal drug delivery, overlapping in cancer vaccine, viral vaccine, and dose-sparing use cases.
  • PharmaJet: PharmaJet provides needle-free jet injection systems (Stratis and Tropis) for intradermal and intramuscular vaccine administration. Direct peer in vaccine delivery: targets the same pharmaceutical partners for dose-sparing intradermal administration, with an alternative (jet) mechanism.
  • Micron Biomedical: Micron Biomedical develops dissolvable microneedle patches for vaccines (measles, flu, polio) and is backed by program grants including from the Gates Foundation. Direct peer: same end customer (vaccine developers), same delivery route (intradermal), competing mechanism of action.
  • Nanopass Technologies: Nanopass is an Israeli microneedle company with silicon-based micron-scale needle technologies used for intradermal delivery in vaccines and therapeutics. Closest technology peer: both use semiconductor-process silicon microneedles and target identical intradermal pharmaceutical application areas.
  • Clearside Biomedical: Clearside has the approved suprachoroidal injection platform SCS Microinjector used in Xipere for macular edema and is partnering with retinal therapy developers. Direct Bella-Vue competitor: same suprachoroidal drug delivery procedure, same ophthalmology pharmaceutical customer, same retinal disease indications.

Broad incumbents

  • 3M Drug Delivery Systems: 3M Drug Delivery Systems is a leading manufacturer of transdermal patches and microneedle technologies (via the 3M Microstructured Transdermal System) used by pharmaceutical partners. Broad incumbent: large device manufacturer with adjacent microneedle drug delivery offering, with greater resources and broader commercial reach than Uneedle.
  • Kindeva Drug Delivery: Kindeva Drug Delivery (formerly 3M Drug Delivery) is a contract drug delivery manufacturer offering transdermal, microneedle, and inhalation delivery solutions to pharma partners. Broad incumbent: serves the same pharmaceutical co-development customer set with comparable microneedle and transdermal capabilities at much larger scale.
  • Corium (LTS Lurb): Corium, now part of LTS Lurb, develops transdermal drug delivery systems including microneedle-based platforms. Broad incumbent: established transdermal delivery company with overlapping customer base in pharmaceutical drug delivery, but operating at much greater scale and with broader product portfolio.
  • BD Medical (Becton Dickinson): Becton Dickinson is a global medical device company making injection and drug delivery devices including prefillable syringes, auto-injectors, and intradermal needles. Broad incumbent: dominant incumbent in injection drug delivery with established pharma distribution; potentially positioned as an acquirer or competitor in the microneedle niche.

Others

  • West Pharmaceutical Services: West Pharmaceutical Services is a leading provider of primary packaging, delivery systems, and contract development services for injectable pharmaceutical products. Enabler/ecosystem peer: not a direct microneedle competitor, but the supplier-of-record and contract manufacturer of injection/packaging components used in combination products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Uneedle social profiles

Digital presence

Uneedle compliance and trust

Trust signal

Compliance3 records

Uneedle financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Uneedle leadership team

Management profile

Number of profiles

Profiles2 records

Uneedle funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Uneedle M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Uneedle

What does Uneedle do?

Uneedle designs, develops, and manufactures proprietary silicon microneedle-based drug delivery devices for pharmaceutical partners, organized into two product platforms: Bella-Vue for suprachoroidal ophthalmic injections (targeting retinal diseases such as wet/dry AMD, diabetic retinopathy, and macular edema) and Bella-mu for intradermal injections (used in cancer vaccines, viral infection vaccines, and aesthetic treatments). Lead commercial products include the Bella-Vue 1.0 and Bella-mu 1.4 mm needles, both manufactured in-house at GMP-compliant cleanroom facilities in the Netherlands. The company also provides custom product development services and licenses its proprietary microneedle technology to pharmaceutical companies.

Is Uneedle a public or private company?

Uneedle is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Uneedle founded?

Uneedle was founded in 2008. It employs 11 to 50 people.

Where is Uneedle based?

Uneedle is headquartered in Enschede, Netherlands, in the Europe region.

How does Uneedle make money?

Three revenue lines are on record. Silicon Microneedle Product Sales are the primary driver. The others are licensing and custom Product Development.

Who are Uneedle's main competitors?

Direct peers on record are Vaxxas, PharmaJet, Micron Biomedical, Nanopass Technologies and Clearside Biomedical. Broad incumbents are 3M Drug Delivery Systems, Kindeva Drug Delivery, Corium (LTS Lurb) and BD Medical (Becton Dickinson). West Pharmaceutical Services is listed as an others.

Does Uneedle have an API?

No public API is recorded for Uneedle.

What industry is Uneedle in?

Uneedle's product category is Medical Devices - Microneedle Drug Delivery. Its primary akta.pro industry code is HLAHADAM, Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Manila TimesCascade Prodrug and Uneedle Advance Collaboration to Enable Suprachoroidal Delivery of CPD100 for Wet AMDCascade Prodrug Inc. and Uneedle are advancing their collaboration to evaluate CPD100, Cascade's hypoxia-targeted therapeutic, for the treatment of wet age-related macular degeneration, using Uneedle's Bella-Vue suprachoroidal microneedle system for targeted delivery. In vitro studies demonstrated that CPD100 induced cell-cycle arrest and apoptosis in endothelial cells under hypoxic conditions while preserving retinal cell viability. The companies have an ongoing preclinical proof-of-concept study underway and plan to seek an initial FDA meeting in Q4 2026, with Cascade also securing funding for CMC activities and GLP-enabling studies to support IND clearance.BioSpaceCascade Prodrug and Uneedle Advance Collaboration to Enable Suprachoroidal Delivery of CPD100 for Wet AMDCascade Prodrug and Uneedle are advancing CPD100, a hypoxia-targeted therapeutic, for wet AMD using Uneedle's Bella-Vue suprachoroidal microneedle system. In vitro studies showed CPD100 induced cell-cycle arrest and apoptosis in endothelial cells under hypoxia. The companies plan an initial INTERACT-FDA meeting in Q4 2026.GlobeNewswireCascade Prodrug and Uneedle Advance Collaboration to Enable Suprachoroidal Delivery of CPD100 for Wet AMDCascade Prodrug Inc. and Uneedle announced they are advancing their collaboration to evaluate Cascade's hypoxia-targeted therapeutic CPD100 for wet age-related macular degeneration using Uneedle's Bella-Vue suprachoroidal microneedle system for targeted delivery to the choroid. In vitro studies demonstrated that low concentrations of CPD100 induced cell-cycle arrest and apoptosis in endothelial cells under hypoxic conditions while preserving retinal cell viability. The companies have an ongoing preclinical proof-of-concept study underway and are targeting an initial INTERACT-FDA meeting in Q4 2026 to support IND clearance and subsequent clinical development.Stock TitanBriaCell inks Uneedle MoU for Bria-IMT deliveryBriaCell Therapeutics has entered into a Memorandum of Understanding with Uneedle, a Netherlands-based microneedle drug-delivery company, to support the commercial readiness of Uneedle's proprietary microneedle technology for intradermal administration of BriaCell's lead Phase 3 clinical candidate, Bria-IMT, for metastatic breast cancer. The non-binding MoU is intended to establish a plan for scaling Uneedle's microneedle devices for commercial quantities, contingent upon successful regulatory approval of Bria-IMT. Uneedle's microneedle technology is currently being used in BriaCell's ongoing pivotal Phase 3 study (ClinicalTrials.gov identifier: NCT06072612).GlobeNewswireBriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™BriaCell Therapeutics has entered into a Memorandum of Understanding with Uneedle, a Netherlands-based microneedle drug-delivery company, to support commercial readiness of BriaCell's lead Phase 3 clinical candidate Bria-IMT for metastatic breast cancer treatment using Uneedle's proprietary intradermal microneedle technology. The technology is currently being used in BriaCell's pivotal Phase 3 study and is designed to enable faster, more convenient administration while enhancing the patient and provider experience. All activities under the non-binding MoU are contingent upon successful regulatory approval of Bria-IMT in the relevant jurisdictions.